December 23rd 2020, 3:44pm
The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.
December 23rd 2020, 1:00pm
The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma, as a first-line and second-line therapy for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
December 17th 2020, 12:00pm
Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.
December 15th 2020, 11:00pm
A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.
December 10th 2020, 1:00pm
A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).
December 8th 2020, 7:00pm
SEQUOIA arm D study results show better outcomes are possible for patients with 17p-deletion CLL, explained Ian Flynn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.
December 2nd 2020, 9:15pm
Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.
November 26th 2020, 2:00pm
Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
November 23rd 2020, 12:30pm
Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.
November 21st 2020, 3:15pm
A new report finds including rituximab in first-line therapy for diffuse large B-cell lymphoma (DLBCL) results in better overall outcomes that more than offset the higher initial cost of therapy.
